Following the acquisition of Henlix Biotech and Tridem Pharma in the span of a week, Shanghai Fosun Pharmaceutical Group, the healthcare unit of Fosun International Ltd., achieved a new milestone, with its market cap at a record high of over CNY100bn on Nov. 6.
Investors appeared to back Fosun Pharma’s plans and the firm’s stock surged 5.1% on the China main board, and 2.11%...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

